Definitive Contract HHSN268200800009C

<p>This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Heart, Lung, and Blood Institute (NHLBI), a civilian agency, to Prolong Pharmaceuticals, Inc. for the &quot;Production of Pegylated Hemoglobin&quot;. The definitive, firm-fixed price contract has a ceiling value of $101,339.00 and a period of performance ending on January 31, 2009. The contract is focused on biomedical, applied/exploratory research and development.</p>

<p>This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Heart Lung and Blood Institute (NHLBI), a civilian agency within the U.S. Department of Health and Human Services. The contract, valued at $279,113, was awarded to Gwathmey, Inc. on August 26, 2009 for biomedical (applied/exploratory) research. The contract has a firm fixed price pricing type and a completion date of September 30, 2010.</p>

<p>This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Heart, Lung, and Blood Institute (NHLBI), a civilian agency, to Nanoshell Company, LLC, a woman-owned small business. The contract, valued at $148,235.00, is for research into using haptoglobin as a treatment to reduce complications of sickle cell disease. The contract has a firm-fixed price and was awarded on August 1, 2012, with a target completion date of March 15, 2013.</p>

<p>This is a federal contract award from the National Heart Lung and Blood Institute, a civilian agency, to Biomedomics, Inc., a minority-owned, for-profit manufacturer of goods, for a Small Business Innovation Research (SBIR) Program Phase I research project. The contract has a Firm Fixed Price of $99,932.00 and was awarded on December 1, 2009 with a completion date of May 31, 2010. The contract is set aside for small businesses. No additional subcontractors or context are provided.</p>

This is a federal contract award from the National Heart Lung and Blood Institute, a civilian agency, to New Health Sciences, Inc. (doing business as Hemanext Inc.), a small business manufacturer. The $1,660,011.00 contract is for the development of a novel, low-cost blood storage system that will deliver higher quality red blood cells, thereby reducing the harmful consequences of transfusion therapy. This contract is part of the SBIR (Small Business Innovation Research) Phase I program, under...

This federal contract award, identified as HHSN268201200064C, was made by the National Heart Lung and Blood Institute (NHLBI), a civilian agency of the U.S. government, to HDL Apomics LLC, a small business. The $139,291.00 Firm Fixed Price contract is for &quot;OTHER FUNCTIONS-ANTIBODY PROTEOMICS FOR MEASURING LIPOPROTEIN SUB-POPULATIONS&quot; under the SBIR TOPIC 64 PHASE 1 - NOVEL TECHNOLOGIES FOR ASSESSING LIPOPROTEIN SUB-FRACTIONS program. The contract has a total small business set-aside...

This federal contract award with ID HHSN268200700021C was made by the National Heart Lung and Blood Institute, a civilian agency within the Department of Health and Human Services, to Biosurfaces Inc., a for-profit small business. The $100,000 firm fixed-price contract is for the development of critical technologies for ventricular assist devices under the SBIR Phase I program. The contract has a period of performance from September 30, 2007 to June 17, 2009. Biosurfaces Inc. specializes in...

This is a $1,524,172.57 definitive contract awarded by the National Heart Lung and Blood Institute (NHLBI), a civilian agency, to Cytosorbents Medical Inc. (Cytosorbents) to develop HemoDefend, a hemocompatible, highly porous polymer bead technology designed to broadly remove free hemoglobin, potassium, reactive antibodies, and inflammatory or reactive substances from blood. The contract has a total small business set aside designation, indicating Cytosorbents as the prime contractor. Based on...

<p>This is a $99,963.00 firm-fixed-price definitive contract awarded by the National Heart Lung and Blood Institute, a civilian agency under the U.S. Department of Health and Human Services, to Heartflow, Inc., a for-profit Subchapter S corporation. The contract is for biomedical (applied/exploratory) research and development, with a period of performance from August 1, 2008 to April 1, 2009. The contract has a total small business set-aside designation.</p>

<p>This is a Small Business Innovation Research (SBIR) Program Phase I contract awarded by the U.S. Department of Health and Human Services (HHS) to Buffalo Biolabs, LLC, a small business located in Buffalo, New York. The contract is for basic physical sciences research with a firm fixed price of $149,987 and a period of performance ending on March 31, 2010. The contract was awarded on September 30, 2009 and has a total small business set-aside designation.</p>